NCT03672565

SMART ERP for the Behavioral Treatment of Youth With Obsessive Compulsive Disorder (OCD)

Completed NA Last updated 30 September 2021

What this trial tests

NA trial testing Phase One: Standardized Brief Intensive ERP in Obsessive-Compulsive Disorder in 100 participants. Completed in 27 August 2021.

Timeline

1 October 2018

Primary endpoint
27 August 2021

27 August 2021

Quick facts

Lead sponsor	University of British Columbia
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	1 October 2018
Primary completion	27 August 2021
Estimated completion	27 August 2021
Sites	1 location across Canada

Drugs / interventions tested

• Phase One: Standardized Brief Intensive ERP
• Phase Two: Flexible Patient Driven Intensive ERP
• Follow-Up Phase: Booster Calls

Conditions studied

• Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →

Sponsor

University of British Columbia

Who can join

Adults 7 to 19, any sex, with Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized pilot study examines a graduated behavioral treatment approach for youth with obsessive compulsive disorder. Youth will be randomized to receive treatment in the community or at the hospital. In the first stage, youth receive an intro session and two 3-hour ERP sessions. Youth will be assessed for OCD recovery. Recovered youth enter follow-up. Still affected youth enter the second stage, where they will can select to receive up to four additional ERP sessions (one per week). In follow-up, youth will receive three 30 minute weekly calls and will be reassessed at 1- and 6-months following treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Effects of Treatment Setting on Outcomes of Flexibly-Dosed Intensive Cognitive Behavioral Therapy for Pediatric OCD: A Randomized Controlled Pilot Trial.
   Selles RR, Naqqash Z, Best JR, Franco-Yamin D, et al · · 2021 · cited 6× · PMID 34079488 · DOI 10.3389/fpsyt.2021.669494